Maruho

Privately held: no public share price

Assets

(3 total)
3Total Assets
2Approved
0Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
nemolizumab(Nemluvio)
Approved
IL-31 receptor AMonoclonal antibody
Atopic DermatitisPrurigo Nodularis
Approved
JAK1/2Small molecule
Atopic DermatitisPrurigo NodularisVitiligoHidradenitis Suppurativa
Phase 2
MRGPRX2Small molecule
MigraineUrticaria
Chronic Inducible Urticaria

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
nemolizumab · NemluvioPhase 2Chronic Pruritus of Unknown Origin
Est. primary completion 2026-12 · NCT07074977 · CT.gov ↗
What to watch
2027 (3)
April 2027 (1)
Ruxolitinib (Opzelura)Phase 3NonSegmental Vitiligo
Est. primary completion 2027-04-30 · NCT06804811 · CT.gov ↗
What to watch
October 2027 (2)
EVO756Phase 2Migraine
Est. primary completion 2027-10 · NCT07616128 · CT.gov ↗
What to watch
nemolizumab · NemluvioPhase 3Atopic Dermatitis
Est. primary completion 2027-10-28 · NCT07762833 · CT.gov ↗
What to watch
2028 (3)
May 2028 (1)
nemolizumab · NemluvioPhase 2Systemic Sclerosis
Est. primary completion 2028-05-28 · NCT07047690 · CT.gov ↗
What to watch
June 2028 (1)
Ruxolitinib (Opzelura)Phase 3NonSegmental Vitiligo
Est. primary completion 2028-06-05 · NCT06548360 · CT.gov ↗
What to watch
July 2028 (1)
nemolizumab · NemluvioPhase 2Moderate-to-Severe Atopic Dermatitis
Est. primary completion 2028-07-15 · NCT07660835 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 September 2026Topline resultEVO756Phase 2b of EVO756 in atopic dermatitis did not meet its primary endpoint
Evommune · Source ↗
29 July 2026ApprovalRuxolitinib (Opzelura)European Commission approves Opzelura cream for moderate atopic dermatitis
EU, EC · Source ↗
29 June 2026Topline resultEVO756Phase 2b of EVO756 in chronic spontaneous urticaria did not meet its primary endpoint
Evommune · Source ↗
7 May 2026Topline resultRuxolitinib (Opzelura)TRuE-AD4 final 24-week data for Opzelura cream

Financial reports

No financial reports recorded.